Literature DB >> 3929585

Hemodynamic and hormonal effects of high-dose transdermal nitroglycerin in patients with chronic congestive heart failure.

U Elkayam, A Roth, B Henriquez, L Weber, D Tonnemacher, S H Rahimtoola.   

Abstract

The hemodynamic effect of a large dose of nitroglycerin (NTG) (90 mg) given transdermally using a reservoir system was studied in 10 patients with severe, long-standing congestive heart failure. Serial hemodynamic measurements over 24 hours revealed a mild decrease in mean pulmonary artery wedge pressure. However, the change from baseline was significant only at 2 hours (19 +/- 9 vs 27 +/- 6 mm Hg). Mean right atrial pressure fell 1 hour after initiation of therapy, from 12 +/- 7 to 8 +/- 5 mm Hg. However, the change from control was not statistically significant. No significant changes were noted in heart rate, mean blood pressure, cardiac index, and systemic and pulmonary vascular resistance. Individual analysis of the effect of transdermal NTG on pulmonary artery wedge pressure demonstrated at 20% or greater reduction in 8 of 10 patients. However, persistent effect (longer than 8 hours) was seen in only 4 patients. Removal of NTG patches at 24 hours did not result in hemodynamic rebound. Serum catecholamine levels and renin concentration did not change 2 hours and 24 hours after initiation of NTG therapy or after removal of NTG patches. Thus, a large dose (90 mg) of transdermal NTG using a reservoir system results in mild and mostly statistically insignificant hemodynamic effect in patients with chronic severe congestive heart failure. Although a reduction in pulmonary artery wedge pressure is seen in most patients, rapid attenuation of this response is found in many patients and the effect only rarely lasts for 24 hours.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929585     DOI: 10.1016/0002-9149(85)91184-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure.

Authors:  G L Bartels; W J Remme; A C Wiesfeld; F J Kok; M P Look; X H Krauss; H A Kruyssen
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 2.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Use of nitrates in acute and chronic congestive heart failure.

Authors:  K Swedberg
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 4.  Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration.

Authors:  J Abrams
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 5.  Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.

Authors:  P A Todd; K L Goa; H D Langtry
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 6.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 7.  Haemodynamic aspects of nitrate tolerance.

Authors:  L Erhardt
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 8.  Nitrates in congestive heart failure.

Authors:  J Dupuis
Journal:  Cardiovasc Drugs Ther       Date:  1994-06       Impact factor: 3.727

Review 9.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.